Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

A Non-interventional, Multi-centric, Single Country Observational Study to Assess the Safety and Effectiveness of Guselkumab After Ustekinumab (Originator or Biosimilar) in Moderate to Severe Psoriasis Patients in Clinical Routine

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of this study is to assess the effectiveness and safety of guselkumab following a switch from ustekinumab or an ustekinumab biosimilar in participants with moderate to severe psoriasis, a chronic inflammatory skin disease characterized by erythematous, scaly plaques that may be associated with pain and pruritus, in routine clinical practice.

Who May Be Eligible (Plain English)

Who May Qualify: - Must have a confirmed diagnosis of moderate-to-severe plaque psoriasis requiring systemic treatment - Participants who are currently treated with Ustekinumab (either the originator or its biosimilar) and who are medically indicated to switch to Guselkumab - Participants who, based on the Investigator's decision, should initiate treatment with Guselkumab - Participants must understand and be willing and able to answer patient-reported outcomes (PROs) - Must sign an willing to sign a consent form form (ICF) allowing data collection and source data verification in accordance with local requirements Who Should NOT Join This Trial: - Contraindication or hypersensitivity to Guselkumab or any ingredient in the injection solution/liquid - Pregnancy or breastfeeding - Currently enrolled in an interventional study - Currently enrolled in an observational study sponsored or managed by a Janssen company Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion criteria: * Must have a confirmed diagnosis of moderate-to-severe plaque psoriasis requiring systemic treatment * Participants who are currently treated with Ustekinumab (either the originator or its biosimilar) and who are medically indicated to switch to Guselkumab * Participants who, based on the Investigator's decision, should initiate treatment with Guselkumab * Participants must understand and be willing and able to answer patient-reported outcomes (PROs) * Must sign an informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements Exclusion criteria: * Contraindication or hypersensitivity to Guselkumab or any ingredient in the injection solution/liquid * Pregnancy or breastfeeding * Currently enrolled in an interventional study * Currently enrolled in an observational study sponsored or managed by a Janssen company

Locations (1)

LKH-Univ. Klinikum Graz
Graz, Austria